There is little evidence to suggest increased risk
in such cases and caution needs to be exercised
evaluating the amount of years the patient
has been under treatment.
Finally, intravenous delivery of bisphosphonates
for the treatment of cancer is increasing significantly
the doses and the risk for osteonecrosis
and in such cases implant surgery
should be completely avoided.
A newer drug with increasing popularity is Denosumab,
which is a monoclonal antibody.
This is a relatively new drug
and although it was initially introduced
as a safer alternative to bisphosphonates,
it appears it is also increasing the risk for osteonecrosis.
As this is a new drug
and we have little evidence of its potential risks,
extreme caution should be exercised
prior to deciding implant therapy for such patients.
Furthermore, we have certain conditions
that might be compatible with health,
but they indicate susceptibility
and consequently an increased risk for failures.
A typical example of such a condition
is the history of periodontitis, describing patients
who have been in the past diagnosed with periodontitis,
even if they currently enjoy good gingival health.